Interview: Archer Materials' next big step - Biochip beta prototype and 2026 plans

This interview was published by Small Caps.

Archer CEO Simon Ruffell sits down with James Whelan to talk through the company’s next big move.

The interview covers the shift from the Biochip alpha prototype to the beta prototype, why that matters, and how it sets up external testing, preclinical work and future clinical trials.

Simon explains the first planned product, a potassium blood monitoring cartridge, and why this could matter for patients with cardiovascular disease, kidney disease and diabetes. We also look at the regulatory path ahead, including early engagement with the FDA and TGA, what investors should expect over the next 12 to 24 months, and how Archer is thinking about licensing and partnership opportunities with medtech groups and contract manufacturers.

The discussion finishes with a look at Archer’s broader quantum program, including demonstrator qubits and the company’s push to build tangible devices that can be shown to potential partners.